Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 139

1.

Role of a Kinesin Motor in Cancer Cell Mechanics.

Mandal K, Pogoda K, Nandi S, Mathieu S, Kasri A, Klein E, Radvanyi F, Goud B, Janmey PA, Manneville JB.

Nano Lett. 2019 Nov 13;19(11):7691-7702. doi: 10.1021/acs.nanolett.9b02592. Epub 2019 Oct 7.

PMID:
31565944
2.

TEMPORARY REMOVAL: A Consensus Molecular Classification of Muscle-invasive Bladder Cancer.

Kamoun A, de Reyniès A, Allory Y, Sjödahl G, Robertson AG, Seiler R, Hoadley KA, Groeneveld CS, Al-Ahmadie H, Choi W, Castro MAA, Fontugne J, Eriksson P, Mo Q, Kardos J, Zlotta A, Hartmann A, Dinney CP, Bellmunt J, Powles T, Malats N, Chan KS, Kim WY, McConkey DJ, Black PC, Dyrskjøt L, Höglund M, Lerner SP, Real FX, Radvanyi F; Bladder Cancer Molecular Taxonomy Group.

Eur Urol. 2019 Sep 26. pii: S0302-2838(19)30695-5. doi: 10.1016/j.eururo.2019.09.006. [Epub ahead of print]

3.

PLEKHS1: A new molecular marker predicting risk of progression of non-muscle-invasive bladder cancer.

Pignot G, Le Goux C, Vacher S, Schnitzler A, Radvanyi F, Allory Y, Lallemand F, Delongchamps NB, Zerbib M, Terris B, Damotte D, Bieche I.

Oncol Lett. 2019 Oct;18(4):3471-3480. doi: 10.3892/ol.2019.10706. Epub 2019 Aug 2.

4.

Independent Component Analysis for Unraveling the Complexity of Cancer Omics Datasets.

Sompairac N, Nazarov PV, Czerwinska U, Cantini L, Biton A, Molkenov A, Zhumadilov Z, Barillot E, Radvanyi F, Gorban A, Kairov U, Zinovyev A.

Int J Mol Sci. 2019 Sep 7;20(18). pii: E4414. doi: 10.3390/ijms20184414. Review.

5.

Reply to Alexander Yang, Vincent L. Cannataro, Jeffrey P. Townsend's Letter to the Editor, re: Ming-Jun Shi, Xiang-Yu Meng, Philippe Lamy, et al. APOBEC-mediated Mutagenesis as, a Likely Cause of FGFR3 S249C Mutation Over-representation in Bladder Cancer. Eur Urol 2019, 76:9-13.

Shi MJ, Meng XY, Chen CL, Dyrskjøt L, Radvanyi F, Prokunina-Olsson L, Bernard-Pierrot I.

Eur Urol. 2019 Sep 4. pii: S0302-2838(19)30656-6. doi: 10.1016/j.eururo.2019.08.012. [Epub ahead of print] No abstract available.

PMID:
31493961
6.

Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancer.

Borcoman E, De La Rochere P, Richer W, Vacher S, Chemlali W, Krucker C, Sirab N, Radvanyi F, Allory Y, Pignot G, Barry de Longchamps N, Damotte D, Meseure D, Sedlik C, Bieche I, Piaggio E.

Oncoimmunology. 2019 Mar 16;8(5):e1581556. doi: 10.1080/2162402X.2019.1581556. eCollection 2019.

7.

APOBEC-mediated Mutagenesis as a Likely Cause of FGFR3 S249C Mutation Over-representation in Bladder Cancer.

Shi MJ, Meng XY, Lamy P, Banday AR, Yang J, Moreno-Vega A, Chen CL, Dyrskjøt L, Bernard-Pierrot I, Prokunina-Olsson L, Radvanyi F.

Eur Urol. 2019 Jul;76(1):9-13. doi: 10.1016/j.eururo.2019.03.032. Epub 2019 Apr 8.

PMID:
30975452
8.

Assessing reproducibility of matrix factorization methods in independent transcriptomes.

Cantini L, Kairov U, de Reyniès A, Barillot E, Radvanyi F, Zinovyev A.

Bioinformatics. 2019 Nov 1;35(21):4307-4313. doi: 10.1093/bioinformatics/btz225.

9.

TYRO3 as a molecular target for growth inhibition and apoptosis induction in bladder cancer.

Dufour F, Silina L, Neyret-Kahn H, Moreno-Vega A, Krucker C, Karboul N, Dorland-Galliot M, Maillé P, Chapeaublanc E, Allory Y, Stransky N, Haegel H, Menguy T, Duong V, Radvanyi F, Bernard-Pierrot I.

Br J Cancer. 2019 Mar;120(5):555-564. doi: 10.1038/s41416-019-0397-6. Epub 2019 Feb 15.

PMID:
30765874
10.

Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01.

Pascual-Pasto G, Bazan-Peregrino M, Olaciregui NG, Restrepo-Perdomo CA, Mato-Berciano A, Ottaviani D, Weber K, Correa G, Paco S, Vila-Ubach M, Cuadrado-Vilanova M, Castillo-Ecija H, Botteri G, Garcia-Gerique L, Moreno-Gilabert H, Gimenez-Alejandre M, Alonso-Lopez P, Farrera-Sal M, Torres-Manjon S, Ramos-Lozano D, Moreno R, Aerts I, Doz F, Cassoux N, Chapeaublanc E, Torrebadell M, Roldan M, König A, Suñol M, Claverol J, Lavarino C, Carmen de T, Fu L, Radvanyi F, Munier FL, Catalá-Mora J, Mora J, Alemany R, Cascalló M, Chantada GL, Carcaboso AM.

Sci Transl Med. 2019 Jan 23;11(476). pii: eaat9321. doi: 10.1126/scitranslmed.aat9321.

PMID:
30674657
11.

Recurrent activating mutations of PPARγ associated with luminal bladder tumors.

Rochel N, Krucker C, Coutos-Thévenot L, Osz J, Zhang R, Guyon E, Zita W, Vanthong S, Hernandez OA, Bourguet M, Badawy KA, Dufour F, Peluso-Iltis C, Heckler-Beji S, Dejaegere A, Kamoun A, de Reyniès A, Neuzillet Y, Rebouissou S, Béraud C, Lang H, Massfelder T, Allory Y, Cianférani S, Stote RH, Radvanyi F, Bernard-Pierrot I.

Nat Commun. 2019 Jan 16;10(1):253. doi: 10.1038/s41467-018-08157-y.

12.

Design, synthesis, biological evaluation and cellular imaging of imidazo[4,5-b]pyridine derivatives as potent and selective TAM inhibitors.

Baladi T, Aziz J, Dufour F, Abet V, Stoven V, Radvanyi F, Poyer F, Wu TD, Guerquin-Kern JL, Bernard-Pierrot I, Garrido SM, Piguel S.

Bioorg Med Chem. 2018 Nov 1;26(20):5510-5530. doi: 10.1016/j.bmc.2018.09.031. Epub 2018 Sep 25.

PMID:
30309671
13.

Differential transcription factor expression by human epithelial cells of buccal and urothelial derivation.

Hustler A, Eardley I, Hinley J, Pearson J, Wezel F, Radvanyi F, Baker SC, Southgate J.

Exp Cell Res. 2018 Aug 15;369(2):284-294. doi: 10.1016/j.yexcr.2018.05.031. Epub 2018 May 26.

14.

An FGFR3/MYC positive feedback loop provides new opportunities for targeted therapies in bladder cancers.

Mahe M, Dufour F, Neyret-Kahn H, Moreno-Vega A, Beraud C, Shi M, Hamaidi I, Sanchez-Quiles V, Krucker C, Dorland-Galliot M, Chapeaublanc E, Nicolle R, Lang H, Pouponnot C, Massfelder T, Radvanyi F, Bernard-Pierrot I.

EMBO Mol Med. 2018 Apr;10(4). pii: e8163. doi: 10.15252/emmm.201708163.

15.

IGF1R activation and the in vitro antiproliferative efficacy of IGF1R inhibitor are inversely correlated with IGFBP5 expression in bladder cancer.

Neuzillet Y, Chapeaublanc E, Krucker C, De Koning L, Lebret T, Radvanyi F, Bernard-Pierrot I.

BMC Cancer. 2017 Sep 7;17(1):636. doi: 10.1186/s12885-017-3618-5.

16.

SegCorr a statistical procedure for the detection of genomic regions of correlated expression.

Delatola EI, Lebarbier E, Mary-Huard T, Radvanyi F, Robin S, Wong J.

BMC Bioinformatics. 2017 Jul 11;18(1):333. doi: 10.1186/s12859-017-1742-5.

17.

Large-Scale SRM Screen of Urothelial Bladder Cancer Candidate Biomarkers in Urine.

Duriez E, Masselon CD, Mesmin C, Court M, Demeure K, Allory Y, Malats N, Matondo M, Radvanyi F, Garin J, Domon B.

J Proteome Res. 2017 Apr 7;16(4):1617-1631. doi: 10.1021/acs.jproteome.6b00979. Epub 2017 Mar 23.

PMID:
28287737
18.

A prospective multicenter study on bladder cancer: the COBLAnCE cohort.

Benhamou S, Bonastre J, Groussard K, Radvanyi F, Allory Y, Lebret T.

BMC Cancer. 2016 Nov 3;16(1):837.

19.

Bladder Cancer Molecular Taxonomy: Summary from a Consensus Meeting.

Lerner SP, McConkey DJ, Hoadley KA, Chan KS, Kim WY, Radvanyi F, Höglund M, Real FX.

Bladder Cancer. 2016 Jan 7;2(1):37-47.

20.

Identification of targeted therapy for an aggressive subgroup of muscle-invasive bladder cancers.

Lebret T, Neuzillet Y, Houede N, Rebouissou S, Bernard-Pierrot I, De Reynies A, Benhamou S, Allory Y, Radvanyi F.

Mol Cell Oncol. 2015 Jul 9;2(4):e999507. doi: 10.1080/23723556.2014.999507. eCollection 2015 Oct-Dec.

21.

A Parent-of-Origin Effect Impacts the Phenotype in Low Penetrance Retinoblastoma Families Segregating the c.1981C>T/p.Arg661Trp Mutation of RB1.

Eloy P, Dehainault C, Sefta M, Aerts I, Doz F, Cassoux N, Lumbroso le Rouic L, Stoppa-Lyonnet D, Radvanyi F, Millot GA, Gauthier-Villars M, Houdayer C.

PLoS Genet. 2016 Feb 29;12(2):e1005888. doi: 10.1371/journal.pgen.1005888. eCollection 2016 Feb.

22.

L'Epidermal Growth Factor Receptor (EGFR) est une cible thérapeutique pour un sous-groupe de tumeurs de vessie agressives de phénotype de type basal.

Neuzillet Y, Rebouissou S, De Reynies A, Lepage M, Krucker C, Chapeaublanc E, Herault A, Kamoun A, Caillault A, Letouze E, Elarouci N, Decoux Y, Molinie V, Vordos D, Laplanche A, Maille P, Soyeux P, Ofualuka K, Reyal F, Biton A, Sibony M, Paoletti X, Southgate J, Benhamou S, Allory Y, Radvanyi F, Lebret T.

Prog Urol. 2014 Nov;24(13):806. doi: 10.1016/j.purol.2014.08.053. Epub 2014 Oct 30. French. No abstract available.

PMID:
26461580
23.

A Modeling Approach to Explain Mutually Exclusive and Co-Occurring Genetic Alterations in Bladder Tumorigenesis.

Remy E, Rebouissou S, Chaouiya C, Zinovyev A, Radvanyi F, Calzone L.

Cancer Res. 2015 Oct 1;75(19):4042-52. doi: 10.1158/0008-5472.CAN-15-0602. Epub 2015 Aug 3. Erratum in: Cancer Res. 2016 Jan 15;76(2):505.

24.

CoRegNet: reconstruction and integrated analysis of co-regulatory networks.

Nicolle R, Radvanyi F, Elati M.

Bioinformatics. 2015 Sep 15;31(18):3066-8. doi: 10.1093/bioinformatics/btv305. Epub 2015 May 14.

25.

Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2.

Oudard S, Culine S, Vano Y, Goldwasser F, Théodore C, Nguyen T, Voog E, Banu E, Vieillefond A, Priou F, Deplanque G, Gravis G, Ravaud A, Vannetzel JM, Machiels JP, Muracciole X, Pichon MF, Bay JO, Elaidi R, Teghom C, Radvanyi F, Beuzeboc P.

Eur J Cancer. 2015 Jan;51(1):45-54. doi: 10.1016/j.ejca.2014.10.009. Epub 2014 Nov 15.

PMID:
25459391
26.

Independent component analysis uncovers the landscape of the bladder tumor transcriptome and reveals insights into luminal and basal subtypes.

Biton A, Bernard-Pierrot I, Lou Y, Krucker C, Chapeaublanc E, Rubio-Pérez C, López-Bigas N, Kamoun A, Neuzillet Y, Gestraud P, Grieco L, Rebouissou S, de Reyniès A, Benhamou S, Lebret T, Southgate J, Barillot E, Allory Y, Zinovyev A, Radvanyi F.

Cell Rep. 2014 Nov 20;9(4):1235-45. doi: 10.1016/j.celrep.2014.10.035. Epub 2014 Nov 13.

27.

Pepper: cytoscape app for protein complex expansion using protein-protein interaction networks.

Winterhalter C, Nicolle R, Louis A, To C, Radvanyi F, Elati M.

Bioinformatics. 2014 Dec 1;30(23):3419-20. doi: 10.1093/bioinformatics/btu517. Epub 2014 Aug 18.

28.

EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype.

Rebouissou S, Bernard-Pierrot I, de Reyniès A, Lepage ML, Krucker C, Chapeaublanc E, Hérault A, Kamoun A, Caillault A, Letouzé E, Elarouci N, Neuzillet Y, Denoux Y, Molinié V, Vordos D, Laplanche A, Maillé P, Soyeux P, Ofualuka K, Reyal F, Biton A, Sibony M, Paoletti X, Southgate J, Benhamou S, Lebret T, Allory Y, Radvanyi F.

Sci Transl Med. 2014 Jul 9;6(244):244ra91. doi: 10.1126/scitranslmed.3008970.

29.

Genome-wide association study yields variants at 20p12.2 that associate with urinary bladder cancer.

Rafnar T, Sulem P, Thorleifsson G, Vermeulen SH, Helgason H, Saemundsdottir J, Gudjonsson SA, Sigurdsson A, Stacey SN, Gudmundsson J, Johannsdottir H, Alexiusdottir K, Petursdottir V, Nikulasson S, Geirsson G, Jonsson T, Aben KK, Grotenhuis AJ, Verhaegh GW, Dudek AM, Witjes JA, van der Heijden AG, Vrieling A, Galesloot TE, De Juan A, Panadero A, Rivera F, Hurst C, Bishop DT, Sak SC, Choudhury A, Teo MT, Arici C, Carta A, Toninelli E, de Verdier P, Rudnai P, Gurzau E, Koppova K, van der Keur KA, Lurkin I, Goossens M, Kellen E, Guarrera S, Russo A, Critelli R, Sacerdote C, Vineis P, Krucker C, Zeegers MP, Gerullis H, Ovsiannikov D, Volkert F, Hengstler JG, Selinski S, Magnusson OT, Masson G, Kong A, Gudbjartsson D, Lindblom A, Zwarthoff E, Porru S, Golka K, Buntinx F, Matullo G, Kumar R, Mayordomo JI, Steineck DG, Kiltie AE, Jonsson E, Radvanyi F, Knowles MA, Thorsteinsdottir U, Kiemeney LA, Stefansson K.

Hum Mol Genet. 2014 Oct 15;23(20):5545-57. doi: 10.1093/hmg/ddu264. Epub 2014 May 26.

30.

Prediction of recurrence of non muscle-invasive bladder cancer by means of a protein signature identified by antibody microarray analyses.

Srinivasan H, Allory Y, Sill M, Vordos D, Alhamdani MS, Radvanyi F, Hoheisel JD, Schröder C.

Proteomics. 2014 Jun;14(11):1333-42. doi: 10.1002/pmic.201300320. Epub 2014 Apr 29.

PMID:
24610664
31.

PRC2-independent chromatin compaction and transcriptional repression in cancer.

Vallot C, Hérault A, Boyle S, Bickmore WA, Radvanyi F.

Oncogene. 2015 Feb 5;34(6):741-51. doi: 10.1038/onc.2013.604. Epub 2014 Jan 27.

PMID:
24469045
32.

Integrative modelling of the influence of MAPK network on cancer cell fate decision.

Grieco L, Calzone L, Bernard-Pierrot I, Radvanyi F, Kahn-Perlès B, Thieffry D.

PLoS Comput Biol. 2013 Oct;9(10):e1003286. doi: 10.1371/journal.pcbi.1003286. Epub 2013 Oct 24. Erratum in: PLoS Comput Biol. 2013 Nov;9(11). doi:10.1371/annotation/90e5e4be-952b-42b8-b56d-46baae3479ed.

33.

New aminopyrimidine derivatives as inhibitors of the TAM family.

Traoré T, Cavagnino A, Saettel N, Radvanyi F, Piguel S, Bernard-Pierrot I, Stoven V, Legraverend M.

Eur J Med Chem. 2013;70:789-801. doi: 10.1016/j.ejmech.2013.10.037. Epub 2013 Oct 22.

PMID:
24239626
34.

A siRNA screen identifies RAD21, EIF3H, CHRAC1 and TANC2 as driver genes within the 8q23, 8q24.3 and 17q23 amplicons in breast cancer with effects on cell growth, survival and transformation.

Mahmood SF, Gruel N, Chapeaublanc E, Lescure A, Jones T, Reyal F, Vincent-Salomon A, Raynal V, Pierron G, Perez F, Camonis J, Del Nery E, Delattre O, Radvanyi F, Bernard-Pierrot I.

Carcinogenesis. 2014 Mar;35(3):670-82. doi: 10.1093/carcin/bgt351. Epub 2013 Oct 22.

PMID:
24148822
35.

An essential role for decorin in bladder cancer invasiveness.

El Behi M, Krumeich S, Lodillinsky C, Kamoun A, Tibaldi L, Sugano G, De Reynies A, Chapeaublanc E, Laplanche A, Lebret T, Allory Y, Radvanyi F, Lantz O, Eiján AM, Bernard-Pierrot I, Théry C.

EMBO Mol Med. 2013 Dec;5(12):1835-51. doi: 10.1002/emmm.201302655. Epub 2013 Oct 20.

36.

PI3K/AKT pathway activation in bladder carcinogenesis.

Calderaro J, Rebouissou S, de Koning L, Masmoudi A, Hérault A, Dubois T, Maille P, Soyeux P, Sibony M, de la Taille A, Vordos D, Lebret T, Radvanyi F, Allory Y.

Int J Cancer. 2014 Apr 15;134(8):1776-84. doi: 10.1002/ijc.28518. Epub 2013 Oct 24.

37.

Rubinstein-Taybi syndrome predisposing to non-WNT, non-SHH, group 3 medulloblastoma.

Bourdeaut F, Miquel C, Richer W, Grill J, Zerah M, Grison C, Pierron G, Amiel J, Krucker C, Radvanyi F, Brugieres L, Delattre O.

Pediatr Blood Cancer. 2014 Feb;61(2):383-6. doi: 10.1002/pbc.24765. Epub 2013 Sep 20.

PMID:
24115570
38.

PPAPDC1B and WHSC1L1 are common drivers of the 8p11-12 amplicon, not only in breast tumors but also in pancreatic adenocarcinomas and lung tumors.

Mahmood SF, Gruel N, Nicolle R, Chapeaublanc E, Delattre O, Radvanyi F, Bernard-Pierrot I.

Am J Pathol. 2013 Nov;183(5):1634-1644. doi: 10.1016/j.ajpath.2013.07.028. Epub 2013 Sep 17.

PMID:
24051013
39.

HMCan: a method for detecting chromatin modifications in cancer samples using ChIP-seq data.

Ashoor H, Hérault A, Kamoun A, Radvanyi F, Bajic VB, Barillot E, Boeva V.

Bioinformatics. 2013 Dec 1;29(23):2979-86. doi: 10.1093/bioinformatics/btt524. Epub 2013 Sep 9.

40.

[Update on FGFR3 mutation and multiple regional epigenetic silencing (MRES) phenotype in urothelial carcinogenesis].

Masson-Lecomte A, Vordos D, de la Taille A, Neuzillet Y, Radvanyi F, Allory Y.

Prog Urol. 2013 Feb;23(2):96-8. doi: 10.1016/j.purol.2012.12.003. Epub 2013 Jan 5. French.

PMID:
23352301
41.

A meta-analysis of the relationship between FGFR3 and TP53 mutations in bladder cancer.

Neuzillet Y, Paoletti X, Ouerhani S, Mongiat-Artus P, Soliman H, de The H, Sibony M, Denoux Y, Molinie V, Herault A, Lepage ML, Maille P, Renou A, Vordos D, Abbou CC, Bakkar A, Asselain B, Kourda N, El Gaaied A, Leroy K, Laplanche A, Benhamou S, Lebret T, Allory Y, Radvanyi F.

PLoS One. 2012;7(12):e48993. doi: 10.1371/journal.pone.0048993. Epub 2012 Dec 13.

42.

Inhibitors of the TAM subfamily of tyrosine kinases: synthesis and biological evaluation.

Suárez RM, Chevot F, Cavagnino A, Saettel N, Radvanyi F, Piguel S, Bernard-Pierrot I, Stoven V, Legraverend M.

Eur J Med Chem. 2013 Mar;61:2-25. doi: 10.1016/j.ejmech.2012.06.005. Epub 2012 Jun 12.

PMID:
22749189
43.

Deregulation of Rab and Rab effector genes in bladder cancer.

Ho JR, Chapeaublanc E, Kirkwood L, Nicolle R, Benhamou S, Lebret T, Allory Y, Southgate J, Radvanyi F, Goud B.

PLoS One. 2012;7(6):e39469. doi: 10.1371/journal.pone.0039469. Epub 2012 Jun 19.

44.

CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma.

Rebouissou S, Hérault A, Letouzé E, Neuzillet Y, Laplanche A, Ofualuka K, Maillé P, Leroy K, Riou A, Lepage ML, Vordos D, de la Taille A, Denoux Y, Sibony M, Guyon F, Lebret T, Benhamou S, Allory Y, Radvanyi F.

J Pathol. 2012 Jul;227(3):315-24. doi: 10.1002/path.4017. Epub 2012 May 8.

PMID:
22422578
45.

Evaluation of predictive models in daily practice for the identification of patients with Lynch syndrome.

Tresallet C, Brouquet A, Julié C, Beauchet A, Vallot C, Ménégaux F, Mitry E, Radvanyi F, Malafosse R, Rougier P, Nordlinger B, Laurent-Puig P, Boileau C, Emile JF, Muti C, Penna C, Hofmann-Radvanyi H.

Int J Cancer. 2012 Mar 15;130(6):1367-77. doi: 10.1002/ijc.26144. Epub 2011 Jul 25.

46.

Gene List significance at-a-glance with GeneValorization.

Brancotte B, Biton A, Bernard-Pierrot I, Radvanyi F, Reyal F, Cohen-Boulakia S.

Bioinformatics. 2011 Apr 15;27(8):1187-9. doi: 10.1093/bioinformatics/btr073. Epub 2011 Feb 23.

47.

A novel epigenetic phenotype associated with the most aggressive pathway of bladder tumor progression.

Vallot C, Stransky N, Bernard-Pierrot I, Hérault A, Zucman-Rossi J, Chapeaublanc E, Vordos D, Laplanche A, Benhamou S, Lebret T, Southgate J, Allory Y, Radvanyi F.

J Natl Cancer Inst. 2011 Jan 5;103(1):47-60. doi: 10.1093/jnci/djq470. Epub 2010 Dec 20.

48.

Milk fat globule--epidermal growth factor--factor VIII (MFGE8)/lactadherin promotes bladder tumor development.

Sugano G, Bernard-Pierrot I, Laé M, Battail C, Allory Y, Stransky N, Krumeich S, Lepage ML, Maille P, Donnadieu MH, Abbou CC, Benhamou S, Lebret T, Sastre-Garau X, Amigorena S, Radvanyi F, Théry C.

Oncogene. 2011 Feb 10;30(6):642-53. doi: 10.1038/onc.2010.446. Epub 2010 Oct 18.

PMID:
20956946
49.

A prognostic DNA signature for T1T2 node-negative breast cancer patients.

Gravier E, Pierron G, Vincent-Salomon A, Gruel N, Raynal V, Savignoni A, De Rycke Y, Pierga JY, Lucchesi C, Reyal F, Fourquet A, Roman-Roman S, Radvanyi F, Sastre-Garau X, Asselain B, Delattre O.

Genes Chromosomes Cancer. 2010 Dec;49(12):1125-34. doi: 10.1002/gcc.20820.

PMID:
20842727
50.

Mosaicism for oncogenic G12D KRAS mutation associated with epidermal nevus, polycystic kidneys and rhabdomyosarcoma.

Bourdeaut F, Hérault A, Gentien D, Pierron G, Ballet S, Reynaud S, Paris R, Schleiermacher G, Baumann C, Philippe-Chomette P, Gauthier-Villars M, Peuchmaur M, Radvanyi F, Delattre O.

J Med Genet. 2010 Dec;47(12):859-62. doi: 10.1136/jmg.2009.075374. Epub 2010 Aug 30.

PMID:
20805368

Supplemental Content

Loading ...
Support Center